Core Insights - AngioDynamics, Inc. (ANGO) reported a pro-forma adjusted loss per share of 10 cents for the first quarter of fiscal 2026, an improvement from the adjusted loss of 11 cents in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 14 cents [1][7] - Pro-forma revenues for the fiscal first quarter reached $75.7 million, reflecting a year-over-year increase of 12.2% and surpassing the Zacks Consensus Estimate by 4.8% [3][7] - The company raised its fiscal 2026 sales outlook to a range of $308-$313 million, up from the previous guidance of $305-$310 million, driven by strong performance in the Med Tech segment [15][21] Revenue Performance - U.S. net revenues for the quarter totaled $66.5 million, up 11.7% year over year, exceeding the estimate of $62.3 million [6] - Pro-forma international revenues were $9.3 million, a 15.6% increase from the previous year, although below the projected $10.2 million [8] - The Med Tech segment's pro-forma net sales were $35.3 million, a 26.1% year-over-year increase, outperforming the estimate of $32.7 million [9][10] Segment Analysis - The growth in the Med Tech segment was primarily driven by increased sales of the Auryon platform, which generated $16.5 million (up 20.1% year over year), and Mechanical Thrombectomy revenues of $11.3 million (up 41.2% year over year) [10][19] - Pro-forma Med Device revenues totaled $40.5 million, reflecting a modest increase of 2.3% from the prior year, slightly above the estimate of $39.9 million [11] Margin and Expense Analysis - Pro forma gross profit rose 14% to $41.9 million, with the gross margin expanding by 90 basis points to 55.3%, surpassing the projected margin of 54.2% [12] - Sales and marketing expenses increased by 9.9% year over year to $28.1 million, while research and development expenses rose 2.1% to $6.4 million [13] Cash Position - AngioDynamics ended the first quarter of fiscal 2026 with cash and cash equivalents of $38.8 million, down from $55.9 million at the end of fiscal 2025, with no debt on its balance sheet [14] Future Outlook - The company expects Med Tech revenue growth to be in the range of 14-16%, up from the previous guidance of 12-15%, while Med Device revenue growth is projected to remain flat compared to fiscal 2025 [15] - Management anticipates a $4-$6 million impact from tariffs on overall performance, with adjusted loss per share projected between 33 cents and 23 cents [16]

Core Insights - AngioDynamics reported a strong first quarter for fiscal year 2026, with net sales reaching $75.7 million, reflecting a year-over-year growth of 12.2% [2][7] - The Med Tech segment experienced significant growth, with net sales of $35.3 million, marking a 26.1% increase compared to the previous year [2][8] - The company continues to focus on operational excellence and innovative technologies to drive profitable growth and enhance patient care [4][5] Financial Performance - Net sales for the first quarter of fiscal year 2026 were $75.7 million, an increase of 12.2% from the prior year [2][7] - Med Tech net sales were $35.3 million, a 26.1% increase from $28.0 million in the prior-year period [2][8] - Med Device net sales were $40.4 million, a 2.3% increase compared to $39.5 million in the prior-year period [9] Profitability Metrics - The company reported a GAAP gross margin of 55.3%, which is 90 basis points higher than the first quarter of fiscal 2025 [10] - Adjusted EBITDA for the first quarter was $2.2 million, compared to a loss of $0.2 million in the prior year [12] - The company recorded a GAAP net loss of $10.9 million, or a loss per share of $0.26, while the adjusted net loss was $4.2 million, or a loss per share of $0.10 [11][12] Cash Flow and Guidance - The company ended the first quarter with $38.8 million in cash and cash equivalents, down from $55.9 million at the end of the previous quarter [14] - AngioDynamics expects to be cash flow positive for the full fiscal year 2026 [5][13] - The company raised its full-year guidance for net sales, Med Tech net sales growth, Adjusted EBITDA, and Adjusted EPS [5][19] Clinical Developments - The first patients were enrolled in the AMBITION BTK and RECOVER-AV clinical trials, demonstrating the company's commitment to advancing clinical evidence [15][16] - Results from the NanoKnife PRESERVE study were published, showing promising outcomes for prostate cancer treatment [18]

Core Insights - AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 3 cents for the fourth quarter of fiscal 2025, which is an improvement from a loss of 6 cents in the same quarter last year and better than the Zacks Consensus Estimate of a loss of 13 cents [1][2][9] Financial Performance - The pro forma adjusted loss per share for the fourth quarter of fiscal 2025 was also 3 cents, compared to 5 cents in the year-ago quarter [2][3] - The GAAP loss per share was 15 cents, an improvement from 33 cents in the prior year [2][3] - Full-year fiscal 2025 adjusted loss per share was 15 cents, better than the 38 cents reported in fiscal 2024 and the Zacks Consensus Estimate of a loss of 29 cents [3] - Total revenues for the fourth quarter reached $80.2 million, reflecting a year-over-year increase of 12.9% and exceeding the Zacks Consensus Estimate by 7.5% [4][9] - Full-year fiscal 2025 revenues were $292.5 million, a decline of 3.8% from the previous year but still above the Zacks Consensus Estimate by 1.9% [5][6] Revenue Breakdown - U.S. net revenues for the fourth quarter were $67.5 million, up 11.1% year over year [7] - International revenues were $12.7 million, representing a 23.8% increase from the prior year [8] Segment Analysis - Med Tech revenues in the fourth quarter were $35.8 million, a 22% increase year over year [10][11] - Med Device revenues totaled $44.4 million, up 6.5% from the year-ago period [13] Margin and Expense Analysis - Pro forma gross profit increased by 9.4% to $42.2 million, but the gross margin contracted by 161 basis points to 52.7% [14] - Sales and marketing expenses rose by 7.6% to $26.4 million, while research and development expenses decreased by 1.9% to $6.6 million [15] Cash Position - AngioDynamics ended fiscal 2025 with cash and cash equivalents of $55.9 million, down from $76.1 million at the end of fiscal 2024 [17] - The company reported no debt on its balance sheet and a cumulative net cash used in operating activities of $10.1 million, compared to $28.2 million a year ago [17] Future Guidance - For fiscal 2026, AngioDynamics expects net sales to be between $305 million and $310 million, indicating growth of 4-6% from fiscal 2025 [18] - The company anticipates Med Tech revenue growth of 12-15%, while Med Device revenue growth is projected to be flat [18] - The adjusted loss per share is expected to range between 35 cents and 25 cents, with the Zacks Consensus Estimate at a loss of 24 cents per share [19] Market Developments - AngioDynamics received a CPT Category I Code for Irreversible Electroporation (IRE) for treating pancreatic lesions, effective January 1, 2027, which expands the reimbursement pathway for NanoKnife [22]